<?xml version="1.0" encoding="UTF-8"?>
<ref id="B232-marinedrugs-17-00304" class="ref">
 <label class="label">232.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Popa-Wagner</surname>
    <given-names class="given-names">A.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Mitran</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Sivanesan</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Chang</surname>
    <given-names class="given-names">E.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Buga</surname>
    <given-names class="given-names">A.M.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">ROS and brain diseases: The good, the bad, and the ugly</article-title>
  <source class="source">Oxid. Med. Cell. Longev.</source>
  <year class="year">2013</year>
  <volume class="volume">2013</volume>
  <fpage class="fpage">14</fpage>
  <pub-id pub-id-type="doi" class="pub-id">10.1155/2013/963520</pub-id>
 </element-citation>
</ref>
